title: Novel drug targets for asthma and COPD: lessons learned from in vitro and in vivo models.
abstract: Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent respiratory diseases characterized by airway inflammation, airway obstruction and airway hyperresponsiveness. Whilst current therapies, such as β-agonists and glucocorticoids, may be effective at reducing symptoms, they do not reduce disease progression. Thus, there is a need to identify new therapeutic targets. In this review, we summarize the potential of novel targets or tools, including anti-inflammatories, phosphodiesterase inhibitors, kinase inhibitors, transient receptor potential channels, vitamin D and protease inhibitors, for the treatment of asthma and COPD.
authors.affiliation: Respiratory Pharmacology, National Heart and Lung Institute (NHLI), Imperial College London, UK.
authors.forename: Katie E
authors.initials: KE
authors.lastname: Baker
authors.affiliation: Respiratory Pharmacology, National Heart and Lung Institute (NHLI), Imperial College London, UK.
authors.forename: Sara J
authors.initials: SJ
authors.lastname: Bonvini
authors.affiliation: Lung Health Research Centre, Department of Pharmacology and Therapeutics, University of Melbourne, VIC, Australia.
authors.forename: Chantal
authors.initials: C
authors.lastname: Donovan
authors.affiliation: Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
authors.forename: Rachel E
authors.initials: RE
authors.lastname: Foong
authors.affiliation: University of Groningen, Department of Molecular Pharmacology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen, Groningen Research Institute of Asthma and COPD, GRIAC, Groningen, The Netherlands.
authors.forename: Bing
authors.initials: B
authors.lastname: Han
authors.affiliation: Manitoba Institute of Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
authors.forename: Aruni
authors.initials: A
authors.lastname: Jha
authors.affiliation: Division of Asthma, Allergy and Lung Biology, King's College London, 5th Floor Tower Wing, Guy's Campus, London SE1 9RT, UK.
authors.forename: Yasin
authors.initials: Y
authors.lastname: Shaifta
authors.affiliation: University of Groningen, Department of Molecular Pharmacology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen, Groningen Research Institute of Asthma and COPD, GRIAC, Groningen, The Netherlands.
authors.forename: Marieke
authors.initials: M
authors.lastname: Smit
authors.affiliation: National Heart and Lung Institute Imperial College London, UK.
authors.forename: Jill R
authors.initials: JR
authors.lastname: Johnson
authors.affiliation: Cell Biology, Woolcock Institute of Medical Research, Glebe, NSW 2037, Australia; Discipline of Pharmacology, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: lyn.moir@sydney.edu.au.
authors.forename: Lyn M
authors.initials: LM
authors.lastname: Moir
mesh_terms: D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D050051:Transient Receptor Potential Channels / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use
chemical_list: D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D010726:Phosphodiesterase Inhibitors; D011480:Protease Inhibitors; D047428:Protein Kinase Inhibitors; D050051:Transient Receptor Potential Channels; D014807:Vitamin D
keywords: G-protein coupled receptor; Inflammation; Kinase; Therapeutic targets; Transient receptor potential channel; Vitamin D